-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Virtu Financial LLC Has $189,000 Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)
Virtu Financial LLC Has $189,000 Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)
Virtu Financial LLC boosted its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) by 55.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 67,900 shares of the biotechnology company's stock after buying an additional 24,331 shares during the quarter. Virtu Financial LLC owned approximately 0.07% of Heron Therapeutics worth $189,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Zullo Investment Group Inc. raised its position in shares of Heron Therapeutics by 90.9% during the 1st quarter. Zullo Investment Group Inc. now owns 6,300 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 3,000 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of Heron Therapeutics by 43.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 16,522 shares of the biotechnology company's stock valued at $46,000 after acquiring an additional 5,000 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $48,000. Bridgefront Capital LLC bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $60,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $73,000.
Get Heron Therapeutics alerts:Wall Street Analyst Weigh In
Several analysts have commented on the stock. Evercore ISI dropped their target price on shares of Heron Therapeutics to $15.00 in a research report on Tuesday, November 15th. Cowen lowered their price objective on shares of Heron Therapeutics to $5.50 in a research report on Monday, August 15th. Needham & Company LLC lowered their price objective on shares of Heron Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, November 9th. Finally, StockNews.com upgraded shares of Heron Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, November 17th.
Heron Therapeutics Price Performance
Shares of NASDAQ HRTX opened at $2.54 on Thursday. The firm has a market cap of $301.98 million, a PE ratio of -1.21 and a beta of 0.88. The company has a current ratio of 2.38, a quick ratio of 1.83 and a debt-to-equity ratio of 6.65. Heron Therapeutics, Inc. has a 1-year low of $2.19 and a 1-year high of $10.46. The company has a fifty day moving average price of $3.47 and a 200 day moving average price of $3.55.Heron Therapeutics Company Profile
(Get Rating)
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More
- Get a free copy of the StockNews.com research report on Heron Therapeutics (HRTX)
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Virtu Financial LLC boosted its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) by 55.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 67,900 shares of the biotechnology company's stock after buying an additional 24,331 shares during the quarter. Virtu Financial LLC owned approximately 0.07% of Heron Therapeutics worth $189,000 as of its most recent SEC filing.
根據最近提交給美國證券交易委員會的檔案，Virtu Financial LLC在第二季度將其在蒼鷺治療公司(HRTX-GET評級)的股票持倉提高了55.8%。該機構投資者在本季度額外購買了24,331股後，持有這家生物技術公司的67,900股票。截至最近提交給美國證券交易委員會的檔案，Virtu Financial LLC擁有蒼鷺治療公司約0.07%的股份，價值18.9萬美元。
Several other large investors have also recently bought and sold shares of the company. Zullo Investment Group Inc. raised its position in shares of Heron Therapeutics by 90.9% during the 1st quarter. Zullo Investment Group Inc. now owns 6,300 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 3,000 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of Heron Therapeutics by 43.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 16,522 shares of the biotechnology company's stock valued at $46,000 after acquiring an additional 5,000 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $48,000. Bridgefront Capital LLC bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $60,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $73,000.
其他幾家大型投資者最近也買賣了該公司的股票。Zullo Investment Group Inc.在第一季度將其在Heron Treateutics的股票頭寸提高了90.9%。Zullo Investment Group Inc.在上個季度增持了3,000股後，現在持有這家生物技術公司6,300股股票，價值3.6萬美元。不列顛國協股權服務公司在第二季度將其在蒼鷺治療公司的股票持有量增加了43.4%。在上個季度增持了5000股後，Federal Equity Services LLC現在擁有這家生物技術公司16522股票，價值4.6萬美元。Point72 Hong Kong Ltd在第一季度購買了蒼鷺治療公司的新股，價值48,000美元。BridgeFront Capital LLC在第一季度購買了蒼鷺治療公司的新股份，價值6萬美元。最後，工程師門經理LP在第一季度購買了Heron Treeutics的新股份，價值73,000美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several analysts have commented on the stock. Evercore ISI dropped their target price on shares of Heron Therapeutics to $15.00 in a research report on Tuesday, November 15th. Cowen lowered their price objective on shares of Heron Therapeutics to $5.50 in a research report on Monday, August 15th. Needham & Company LLC lowered their price objective on shares of Heron Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, November 9th. Finally, StockNews.com upgraded shares of Heron Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, November 17th.
幾位分析師對該股發表了評論。在11月15日星期二的一份研究報告中，Evercore ISI將蒼鷺治療公司的股票目標價下調至15.00美元。考恩在8月15日星期一的一份研究報告中將蒼鷺治療公司的股票目標價下調至5.50美元。Needham&Company LLC將蒼鷺治療公司的股票目標價從10.00美元下調至8.00美元，並在11月9日星期三的一份研究報告中為該公司設定了“買入”評級。最後，StockNews.com在11月17日星期四的一份研究報告中將蒼鷺治療公司的股票評級從“賣出”上調為“持有”。
Heron Therapeutics Price Performance
蒼鷺治療公司性價比
Heron Therapeutics Company Profile
蒼鷺治療公司簡介
(Get Rating)
(獲取評級)
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
蒼鷺治療公司是一家生物技術公司，致力於開發治療方法，以滿足未得到滿足的患者需求。該公司的候選產品利用其專有的生物計時器，這是一種藥物輸送技術，只需一次給藥，就能在幾天到幾周的時間內提供一系列短效藥劑的治療水準。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on Heron Therapeutics (HRTX)
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify's Downtrend?
- The Question of a Fed Pivot Isn't If, It's When, Here's Why
- Top 10 Searched Stocks on MarketBeat All-Access
- 3 Dividend Kings With Royally Good Upside
- 免費獲取StockNews.com關於蒼鷺治療的研究報告(HRTX)
- 為什麼你應該避免Carvana，即使它可以避免破產
- 投資者是否聽到了Spotify下跌趨勢的終結？
- 美聯儲軸心的問題不是是否，而是何時，這是為什麼
- 在MarketBeat All-Access上搜索的前10名股票
- 王室利多的3個股息之王
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating).
想看看還有哪些對沖基金持有HRTX嗎？訪問HoldingsChannel.com獲取蒼鷺治療公司(納斯達克代碼：HRTX-GET Rating)的最新13F備案檔案和內幕交易資訊。
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受蒼鷺治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Heron Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧